Mickael Chane-Du splits his time between being a Partner at Olive Tree Capital and serving as Chief Strategy Officer at Adagene, after spending 7 years at Invus focused on oncology investments and 8 years as a sell-side equity research analyst across firms in the US and Europe. He regularly represents Adagene in front of institutional investors, including at the Jefferies and Morgan Stanley healthcare conferences, and he engages closely with the scientific details behind the company's work, such as how its SAFEbody platform performs on protease-masking and conditional activity.